Cystic fibrosis
Specialty treatments for paediatric and adult patients.
Canadian specialty pharmaceutical company
From oncology and haematology to cystic fibrosis, blood products and rare diseases, Pharmet brings specialty therapies to patients in Türkiye through the Foreign Drug List, with the reliability and continuity that complex treatments demand.
About Pharmet
Pharmet Pharmaceutical is a Canadian specialty pharmaceutical company with operations in Canada and Türkiye. We have specialty products added to Türkiye's Foreign Drug List and supply them to clinicians and patients on a patient-by-patient basis, helping them reach therapies that are not yet licensed locally.
Our expertise spans oncology, haematology, cystic fibrosis and other rare diseases. Strong, cooperative relationships with public institutions support smooth access coordination and continuity of treatment.
Products
Ten specialty therapeutic areas, from rare genetic disease to advanced cell therapy and plasma-derived medicines.
Specialty treatments for paediatric and adult patients.
Therapies for rare genetic and metabolic conditions.
Specialty medicines for solid tumours and haemato-oncology.
Specialty medicines for immune-mediated conditions.
Endocrine and hormonal therapies.
Advanced, cell-based therapies for complex conditions.
Specialty medicines for neurological conditions.
Medicines for gynaecological and women's health conditions.
Treatments for blood disorders.
Plasma-derived therapies for immune, bleeding and critical-care needs.
Availability of each therapeutic area depends on its regulatory status and the applicable access route in Türkiye.
Supply of Pharmaceuticals from Abroad · Named Patient Program
Internationally known as Supply of Pharmaceuticals from Abroad or the Named Patient Program (NPP), this pathway allows specialty products that are not yet licensed in Türkiye to be added to the Active Foreign Drug List, the List of Foreign Drugs Supplied by the Turkish Pharmacists' Association (TEB), so they can be supplied patient by patient before Turkish marketing authorisation. Product documentation and institutional arrangements are prepared in parallel, so supply can begin as soon as the prerequisites are met.
Two routes to the Foreign Drug List
Products are added to the Active Foreign Drug List maintained by the Turkish Pharmacists' Association (TEB) and supplied patient by patient.
Where applicable, products are supplied through the Social Security Institution.
We review international authorisation, Turkish regulatory status, clinical evidence and the permitted source of supply.
We prepare the product documentation and support the listing application, whether through the Turkish Pharmacists' Association (TEB) or the Social Security Institution.
Applicable payer conditions and purchase terms are resolved through the authorised channel.
Eligible patient orders are fulfilled with full traceability, supported by safety reporting and timely replenishment.
Subject to eligibility, required TİTCK permissions, applicable funding conditions and supply readiness.
Institutional relationships
We operate actively within the Foreign Drug List channel, built on constructive working relationships with public institutions. Every product is supported by clinical and economic dossiers and by procurement offers covering price, lead time and continuity.
Funding remains subject to product and patient conditions.
Medical engagement
We provide medical information, disease education and safety communication within the scope permitted for each product.
Medical and promotional activities follow each product's regulatory status. Clinical decisions always remain independent.
Supply & quality
Our teams
Scientific information and specialist engagement within the permitted scope.
Payer preparation and coordination of authorised procurement.
Product documentation, quality agreements and safety obligations.
Forecasting, order execution, payment terms and receivables.
Contact
Questions about our therapeutic areas, the access pathway or our work in Türkiye? Reach out and our team will get back to you.